Literature DB >> 34326924

Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids.

Abby Alpert1, David Powell2, Rosalie Liccardo Pacula3.   

Abstract

Overdose deaths from prescription opioid pain relievers nearly quadrupled between 1999 and 2010. We study the consequences of one of the largest supply disruptions to date to abusable opioids - the introduction of an abuse-deterrent version of OxyContin in 2010. Supply-side interventions which limit access to opioids may have the unintended consequence of increasing use of substitute drugs, including heroin. Exploiting cross-state variation in OxyContin exposure, we find that states with the highest initial rates of OxyContin misuse experienced the largest increases in heroin deaths. Our results imply that the recent heroin epidemic is largely due to the reformulation of OxyContin.

Entities:  

Keywords:  I12; I18; abuse-deterrence; heroin; opioids; supply-side drug policy

Year:  2018        PMID: 34326924      PMCID: PMC8317673          DOI: 10.1257/pol.20170082

Source DB:  PubMed          Journal:  Am Econ J Econ Policy        ISSN: 1945-774X


  36 in total

1.  JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations.

Authors:  D M Phillips
Journal:  JAMA       Date:  2000-07-26       Impact factor: 56.272

2.  Effect of abuse-deterrent formulation of OxyContin.

Authors:  Theodore J Cicero; Matthew S Ellis; Hilary L Surratt
Journal:  N Engl J Med       Date:  2012-07-12       Impact factor: 91.245

3.  Do medical marijuana laws reduce addictions and deaths related to pain killers?

Authors:  David Powell; Rosalie Liccardo Pacula; Mireille Jacobson
Journal:  J Health Econ       Date:  2018-02-03       Impact factor: 3.883

4.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.

Authors:  Theodore J Cicero; James A Inciardi; Alvaro Muñoz
Journal:  J Pain       Date:  2005-10       Impact factor: 5.820

5.  The validity of self-reported drug use data: the accuracy of responses on confidential self-administered answered sheets.

Authors:  A V Harrell
Journal:  NIDA Res Monogr       Date:  1997

Review 6.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.

Authors:  Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander
Journal:  Annu Rev Public Health       Date:  2015-01-12       Impact factor: 21.981

Review 7.  The Misuse of Prescription Opioids: A Threat for Europe?

Authors:  Jan van Amsterdam; Wim van den Brink
Journal:  Curr Drug Abuse Rev       Date:  2015

8.  The promotion and marketing of oxycontin: commercial triumph, public health tragedy.

Authors:  Art Van Zee
Journal:  Am J Public Health       Date:  2008-09-17       Impact factor: 9.308

9.  Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.

Authors:  Stephen F Butler; Theresa A Cassidy; Howard Chilcoat; Ryan A Black; Craig Landau; Simon H Budman; Paul M Coplan
Journal:  J Pain       Date:  2012-11-03       Impact factor: 5.820

10.  Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012.

Authors:  Leonard J Paulozzi; Karin A Mack; Jason M Hockenberry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-04       Impact factor: 17.586

View more
  16 in total

1.  Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients.

Authors:  Stephen Crystal; Molly Nowels; Hillary Samples; Mark Olfson; Arthur Robin Williams; Peter Treitler
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.492

2.  A qualitative examination of recent increases in methamphetamine use in a cohort of rural people who use drugs.

Authors:  Elizabeth R Hansen; Shelby Carvalho; Madelyn McDonald; Jennifer R Havens
Journal:  Drug Alcohol Depend       Date:  2021-10-28       Impact factor: 4.492

3.  Has Declining Opioid Dispensing to Cancer Patients Been Tailored to Risk of Opioid Harms?

Authors:  Tarlise N Townsend; Talya Salz; Rebecca L Haffajee; Megan E V Caram; Fumiko Chino; Amy S B Bohnert
Journal:  J Pain Symptom Manage       Date:  2021-10-15       Impact factor: 3.612

4.  ORIGINS OF THE OPIOID CRISIS AND ITS ENDURING IMPACTS.

Authors:  Abby Alpert; William N Evans; Ethan M J Lieber; David Powell
Journal:  Q J Econ       Date:  2021-11-13

5.  Did prescribing laws disproportionately affect opioid dispensing to Black patients?

Authors:  Tarlise N Townsend; Amy S B Bohnert; Pooja Lagisetty; Rebecca L Haffajee
Journal:  Health Serv Res       Date:  2022-03-20       Impact factor: 3.734

6.  CDC Guideline For Opioid Prescribing Associated With Reduced Dispensing To Certain Patients With Chronic Pain.

Authors:  Tarlise Townsend; Magdalena Cerdá; Amy Bohnert; Pooja Lagisetty; Rebecca L Haffajee
Journal:  Health Aff (Millwood)       Date:  2021-11       Impact factor: 9.048

7.  The Impact of Morphine Equivalent Daily Dose Threshold Guidelines on Prescribed Dose in a Workers' Compensation Population.

Authors:  Sara E Heins; Renan C Castillo
Journal:  Med Care       Date:  2020-03       Impact factor: 2.983

Review 8.  New and Emerging Opioid Overdose Risk Factors.

Authors:  Ralph Foglia; Anna Kline; Nina A Cooperman
Journal:  Curr Addict Rep       Date:  2021-04-22

9.  Substitution of Nonpharmacologic Therapy With Opioid Prescribing for Pain During the COVID-19 Pandemic.

Authors:  Byungkyu Lee; Kai-Cheng Yang; Patrick Kaminski; Siyun Peng; Meltem Odabas; Sumedha Gupta; Harold D Green; Yong-Yeol Ahn; Brea L Perry
Journal:  JAMA Netw Open       Date:  2021-12-01

10.  Prescription opioid policies and associations with opioid overdose and related adverse effects.

Authors:  Valerie S Harder; Susan E Varni; Kimberly A Murray; Timothy B Plante; Andrea C Villanti; Daniel L Wolfson; Sanchit Maruti; Kathleen M Fairfield
Journal:  Int J Drug Policy       Date:  2021-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.